Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a Transcatheter Aortic Valve Intervention (TAVI) according to BARC2 criteria (bleeding complications; Mehran et al 2011) and VARC 3 (other complications; Kappetein et al 2012)..
Full description
The secondary objectives of this study are to evaluate the following at 3 months, 6 months and 12 months after TAVI in both groups:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
170 participants in 2 patient groups
Loading...
Central trial contact
Carey Suehs, PhD; Guillaume Cayla, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal